Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.
This weekend almost had its own news cycle.
(A lot happened)
Australia won its first World Cup game…
Its first opening round win since 2006.
The SpaceX IPO went live…
Up 20% on day 1 and soaking up a chunk of investor attention.
The Strait of Hormuz might be closed again…
For, like, the sixth time since the war began.
… and the budget CGT discount question mark still hangs over the small-cap stock industry like a bad smell.
But these are the external factors.
Listed companies CAN’T control this.
What they CAN control is their story…
How often they tell it, and how it lands with investors.
I have a saying.
For someone to notice you, it takes seeing you 11 times.
That’s why I think the conference circuit is such an important mechanism for ASX-listed healthcare stocks to rapidly achieve 11 notices.
It’s also good to just meet people and get away from the desk for a couple of days.
Company CEOs have to do it all.
Not just run the company, but sell the company too.
The way that I like to think about managing newsflow is like hitting a really good serve in a game of tennis.
The ball toss = setting the expectations.
What is the catalyst? And, more importantly… Why does it matter?
The serve = result.
The expectation ‘beat’. The macro driver that lands. The licencing deal that closes.
A serve without a good ball toss will fall flat.
… and no matter how good the ball toss, a bad serve is a bad serve.
(You still have to deliver!)
So conferences are a way to improve the ball toss, set the expectations for the market and start to knock out some of those ‘11 notices’ for investors.
In the last week of July, I’ll be attending three events across Melbourne and Sydney.
I’ll then be heading to Bioshares in Queenstown the following week.
Here is where I’ll be…
Bio Connections Australia
When: 27th July
Where: Melbourne
Conference Type: Industry / Thought Leadership
Registration: Bio Connections Australia
(Use the code P26A8SPK when you sign up for a discount - also make sure to click on the ‘Biotech Rate’ for the cheaper rate)
East Coast Investor Lunch
When: 28th July
Where: Sydney
Conference Type: Investor Lunch
Register: East Coast Investor Lunch
TechKnow
When: 29th July
Where: Sydney (but there is one on the 27th in Melbourne as well)
Conference Type: Company Presentation
Register: TechKnow
When: 6th - 7th August
Where: Queenstown, NZ
Conference Type: Company Presentations / Investment.
Register: Bioshares
If you’re an ASX-listed healthcare stock, these are some great events to present the story.
Also, for investors, a great way to hear a bunch of companies present in quick succession.
If you do see me there, come up and say hi!
Let’s dive in…
The Pulse Check
Dimerix (ASX: DXB) enters a trading halt in relation to an out-licensing agreement. (DXB)
🪑: 🍿
Paradigm Biopharmaceuticals (ASX: PAR) has completed enrolment in its pivotal Phase 3 trial for knee osteoarthritis pain. Interim analysis is set for September 2026. (PAR)
🪑 Huge milestone ticked. Well done.
Sigma Healthcare (ASX: SIG) withdraws from the Boots acquisition process. (SIG)
🪑 The share price dropped from ~$2.90 to ~$2.60 just on the rumours that Sigma was going to acquire Boots.
The shareholders had spoken, so I think that the board got the message and pulled out.
Entropy Neurodynamics (ASX: ENP) progresses its Phase 2 trial for TRP-8803 in Binge Eating Disorder, with DSMB approval for Cohort 2. (ENP)
A big cross-trade went through this morning on Genetic Signatures (ASX: GSS), $650,000 at $0.065:
🪑 All the sellers are looking to get out before the end of the financial year. Is this the last one?
Regal Watch: As of last Wednesday, Regal Funds held just 42 million shares in Opthea (ASX: OPT) - down from 366 million when it first started trading. (OPT)
🪑 Looks like Regal is pretty much all out of Opthea now.
Vita Life Sciences (ASX: VLS) forecasts H1 2026 sales of $46.3M-$47.3M and pre-tax profit of $6.8M-$7.3M. Marginaly higher when compared to H1 2025. (VLS)
Beamtree (ASX: BMT) appoints Gareth Pye as CEO. (BMT)
🪑 18 years at Technology One. Good luck, Gareth!
On Page 23 of Microba’s (ASX: MAP) capital raise presentation, the company highlighted an approach from a private equity fund in the UK to buy out its diagnostics and supplements business, which Microba chose not to proceed with. (MAP)
🪑 This slide answers a lot of the questions surrounding Microba.
FIRST, an answer to the questions around the “significant corporate transaction” that it mentioned in the 4C report.
SECOND, why the capital raise may have taken longer than expected.
See you all tomorrow,
The Armchair Analyst
